Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Deep clinical evidence library with data collected from more than 1,400 subjects demonstrating dramatic improvement over today's standard of care
IONIQ's ProLung Test designated “Breakthrough Device” by US FDA for its life-enhancing potential
More than 25 premier cancer institutions across 3 continents have participated in our clinical trials
Collaborating with medical and scientific experts
Robust, growing intellectual portfolio of 22 issued and filed patents plus expert know-how
Salt Lake City, UT, July 19, 2023 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that Mr. Jared Bauer, CEO, has accepted the Chairmanship of BioHive. Mr. Bauer will continue to lead IONIQ Sciences alongside this appointment. BioHive exists to enhance
Salt Lake City, UT, July 7, 2023 –Medtech Breakthrough has awarded IONIQ Sciences the “Best Diagnostic Testing Solution of 2023″ (link). Our mission is to “break through” the screening status quo to catch cancer early. You and your doctor could know in just 20 minutes
Salt Lake City, UT, June 5, 2023 – IONIQ Sciences envisions a world where your annual check-up includes a Multi-Cancer Screen. In just 20 minutes, you could know – with no needles, no radiation and no surgery. “If there was a test that could reassure people that a lesion
